Celgene Wants PTAB Rethink On Bass' Cancer Drug IP Win
Celgene Corp. has asked the Patent Trial and Appeal Board to rethink its invalidation of several claims in two patents related to the company's cancer drugs Thalomid, Revlimid and Pomalyst, following...To view the full article, register now.
Already a subscriber? Click here to view full article